Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Medtronic
AstraZeneca
Moodys
Mallinckrodt

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Roniciclib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Roniciclib?

Roniciclib is an investigational drug.

There have been 7 clinical trials for Roniciclib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2014.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Bayer, Dana-Farber Cancer Institute, and Yonsei University.

There are five US patents protecting this investigational drug and eighty-nine international patents.

Recent Clinical Trials for Roniciclib
TitleSponsorPhase
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified TumorsBayerPhase 2
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified TumorsDana-Farber Cancer InstitutePhase 2
An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Yonsei UniversityPhase 1/Phase 2

See all Roniciclib clinical trials

Clinical Trial Summary for Roniciclib

Top disease conditions for Roniciclib
Top clinical trial sponsors for Roniciclib

See all Roniciclib clinical trials

US Patents for Roniciclib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Roniciclib   Start Trial FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (Cambridge, MA)   Start Trial
Roniciclib   Start Trial Human papilloma virus as predictor of cancer prognosis Foundation Medicine, Inc. (Cambridge, MA) UCL Business PLC (London, GB)   Start Trial
Roniciclib   Start Trial Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine Bayer Intellectual Property GmbH (Monheim, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Colorcon
Moodys
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.